ArticleCancer immunology, immunotherapy : CII2020

Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.

Yuki Ozaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.